Contrast removal from coronary sinus for prevention of contrast-induced nephropathy: a review

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Cochran ST, Wong WS, Roe DJ. Predicting angiography-induced acute renal function impairment: clinical risk model. AJR Am. J. Roentgenol. 141(5), 1027–1033 (1983).
  Medline CASGoogle Scholar
• 2. Solomon R. Contrast-medium-induced acute renal failure. Kidney Int. 53(1), 230–242 (1998).
  Medline CASGoogle Scholar
• 3. Morcos SK, Thomsen HS, Webb JA. Contrast-media-induced nephrotoxicity: a consensus report. Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR). Eur. Radiol. 9(8), 1602–1613 (1999). •• Important study discussing risks for contrast induced nephropathy (CIN).
  Medline CASGoogle Scholar
• 4. Berg KJ. Nephrotoxicity related to contrast media. Scand. J. Urol. Nephrol. 34(5), 317–322 (2000).
  Medline CASGoogle Scholar
• 5. Waybill MM, Waybill PN. Contrast media-induced nephrotoxicity: identification of patients at risk and algorithms for prevention. J. Vasc. Interv. Radiol. 12(1), 3–9 (2001).
  Medline CASGoogle Scholar
• 6. Rihal CS, Textor SC, Grill DE et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 105(19), 2259–2264 (2002).
  MedlineGoogle Scholar
• 7. Parfrey PS, Griffiths SM, Barrett BJ et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. N. Engl. J. Med. 320(3), 143–149 (1989).
  Medline CASGoogle Scholar
• 8. Schwab SJ, Hlatky MA, Pieper KS et al. Contrast nephrotoxicity: a randomized controlled trial of a nonionic and an ionic radiographic contrast agent. N. Engl. J. Med. 320(3), 149–153 (1989).
  Medline CASGoogle Scholar
• 9. Rich MW, Crecelius CA. Incidence, risk factors, and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older. A prospective study. Arch. Intern. Med. 150(6), 1237–1242 (1990).
  Medline CASGoogle Scholar
• 10. Stevens MA, McCullough PA, Tobin KJ et al. A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study: Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation. J. Am. Coll. Cardiol. 33(2), 403–411 (1999).
  Medline CASGoogle Scholar
• 11. Hou SH, Bushinsky DA, Wish JB, Cohen JJ, Harrington JT. Hospital-acquired renal insufficiency: a prospective study. Am. J. Med. 74(2), 243–248 (1983).
  Medline CASGoogle Scholar
• 12. Thomsen HS. Guidelines for contrast media from the European Society of Urogenital Radiology. AJR Am. J. Roentgenol. 181(6), 1463–1471 (2003).
  MedlineGoogle Scholar
• 13. Shyu KG, Cheng JJ, Kuan P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J. Am. Coll. Cardiol. 40(8), 1383–1388 (2002).
  Medline CASGoogle Scholar
• 14. Mueller C. Prevention of contrast-induced nephropathy with volume supplementation. Kidney Int. Suppl. (100), S16–9 (2006).
  MedlineGoogle Scholar
• 15. Briguori C, Manganelli F, Scarpato P et al. Acetylcysteine and contrast agent-associated nephrotoxicity. J. Am. Coll. Cardiol. 40(2), 298–303 (2002).
  Medline CASGoogle Scholar
• 16. Baker CSR, Wragg A, Kumar S, De Palma R, Baker LRI, Knight CJ. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J. Am. Coll. Cardiol. 41(12), 2114–2118 (2003).
  MedlineGoogle Scholar
• 17. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am. J. Med. 103(5), 368–375 (1997).
  Medline CASGoogle Scholar
• 18. Gruberg L, Mintz GS, Mehran R et al. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J. Am. Coll. Cardiol. 36(5), 1542–1548 (2000).
  Medline CASGoogle Scholar
• 19. Maeder M, Klein M, Fehr T, Rickli H. Contrast nephropathy: review focusing on prevention. J. Am. Coll. Cardiol. 44(9), 1763–1771 (2004).
  MedlineGoogle Scholar
• 20. Thomsen HS. Current evidence on prevention and management of contrast-induced nephropathy. Eur. Radiol. 17 (Suppl. 6), F33–7 (2007).
  MedlineGoogle Scholar
• 21. Sanaei-Ardekani M, Movahed MR, Movafagh S, Ghahramani N. Contrast-induced nephropathy: a review. Cardiovasc. Revasc. Med. 6(2), 82–8 (2005).
  MedlineGoogle Scholar
• 22. Stacul F, Adam A, Becker CR et al. Strategies to reduce the risk of contrast-induced nephropathy. Am. J. Cardiol. 98(6A), 59K–77K (2006).
  Medline CASGoogle Scholar
• 23. McCullough PA, Choi JP, Feghali GA et al. Contrast-induced acute kidney injury. J. Am. Coll. Cardiol. 68(13), 1465–1473 (2016).
  MedlineGoogle Scholar
• 24. Nanayakkara S, Kaye DM. Device based approaches to the prevention of contrast-induced acute kidney injury. Interv. Cardiol. Clin. 9(3), 395–401 (2020).
  MedlineGoogle Scholar
• 25. Brar SS, Shen AY-J, Jorgensen MB et al. Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial. JAMA 300(9), 1038–1046 (2008).
  Medline CASGoogle Scholar
• 26. Maioli M, Toso A, Leoncini M et al. Sodium bicarbonate versus saline for the prevention of contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. J. Am. Coll. Cardiol. 52(8), 599–604 (2008).
  Medline CASGoogle Scholar
• 27. Mautone A, Brown JR. Contrast-induced nephropathy in patients undergoing elective and urgent procedures. J. Interv. Cardiol. 23(1), 78–85 (2010).
  MedlineGoogle Scholar
• 28. Pucelikova T, Dangas G, Mehran R. Contrast-induced nephropathy. Catheter. Cardiovasc. Interv. 71(1), 62–72 (2008). • Important review discussing CIN.
  MedlineGoogle Scholar
• 29. Fishbane S. N-acetylcysteine in the prevention of contrast-induced nephropathy. Clin. J. Am. Soc. Nephrol. 3(1), 281–287 (2008).
  Medline CASGoogle Scholar
• 30. Venkataraman R. Can we prevent acute kidney injury? Crit. Care Med. 36(Suppl. 4), S166–S171 (2008).
  MedlineGoogle Scholar
• 31. Zagler A, Azadpour M, Mercado C, Hennekens CH. N-acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials. Am. Heart J. 151(1), 140–145 (2006).
  Medline CASGoogle Scholar
• 32. Davidson C, Stacul F, McCullough PA et al. Contrast medium use. Am. J. Cardiol. 98(6A), 42K–58K (2006).
  Medline CASGoogle Scholar
• 33. Aspelin P, Aubry P, Fransson S-G et al. Nephrotoxic effects in high-risk patients undergoing angiography. N. Engl. J. Med. 348(6), 491–499 (2003).
  Medline CASGoogle Scholar
• 34. Solomon R. The role of osmolality in the incidence of contrast-induced nephropathy: a systematic review of angiographic contrast media in high risk patients. Kidney Int. 68(5), 2256–2263 (2005).
  Medline CASGoogle Scholar
• 35. Jo S-H, Youn T-J, Koo B-K et al. Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial. J. Am. Coll. Cardiol. 48(5), 924–930 (2006).
  Medline CASGoogle Scholar
• 36. McCullough PA, Bertrand ME, Brinker JA, Stacul F. A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media. J. Am. Coll. Cardiol. 48(4), 692–699 (2006).
  Medline CASGoogle Scholar
• 37. Barrett BJ, Katzberg RW, Thomsen HS et al. Contrast-induced nephropathy in patients with chronic kidney disease undergoing computed tomography: a double-blind comparison of iodixanol and iopamidol. Invest. Radiol. 41(11), 815–821 (2006).
  Medline CASGoogle Scholar
• 38. Solomon RJ, Natarajan MK, Doucet S et al. Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation 115(25), 3189–3196 (2007).
  MedlineGoogle Scholar
• 39. Reed M, Meier P, Tamhane UU, Welch KB, Moscucci M, Gurm HS. The relative renal safety of iodixanol compared with low-osmolar contrast media: a meta-analysis of randomized controlled trials. JACC Cardiovasc. Interv. 2(7), 645–654 (2009).
  MedlineGoogle Scholar
• 40. From AM, Al Badarin FJ, McDonald FS, Bartholmai BJ, Cha SS, Rihal CS. Iodixanol versus low-osmolar contrast media for prevention of contrast induced nephropathy: meta-analysis of randomized, controlled trials. Circ. Cardiovasc. Interv. 3(4), 351–358 (2010).
  Medline CASGoogle Scholar
• 41. Vogt B, Ferrari P, Schönholzer C et al. Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful. Am. J. Med. 111(9), 692–698 (2001).
  Medline CASGoogle Scholar
• 42. Cruz DN, Perazella MA, Bellomo R et al. Extracorporeal blood purification therapies for prevention of radiocontrast-induced nephropathy: a systematic review. Am. J. Kidney Dis. 48(3), 361–371 (2006).
  MedlineGoogle Scholar
• 43. Marenzi G, Marana I, Lauri G et al. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N. Engl. J. Med. 349(14), 1333–1340 (2003).
  Medline CASGoogle Scholar
• 44. Flaherty MP, Pant S, Patel SV et al. Hemodynamic support with a microaxial percutaneous left ventricular assist device (impella) protects against acute kidney injury in patients undergoing high-risk percutaneous coronary intervention. Circ. Res. 120(4), 692–700 (2017).
  Medline CASGoogle Scholar
• 45. Briguori C, Visconti G, Focaccio A et al. Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): renalGuard System in high-risk patients for contrast-induced acute kidney injury. Circulation 124(11), 1260–1269 (2011).
  Medline CASGoogle Scholar
• 46. Marenzi G, Ferrari C, Marana I et al. Prevention of contrast nephropathy by furosemide with matched hydration: the MYTHOS (Induced Diuresis With Matched Hydration Compared to Standard Hydration for Contrast Induced Nephropathy Prevention) trial. JACC Cardiovasc. Interv. 5(1), 90–97 (2012).
  MedlineGoogle Scholar
• 47. Stone GW, Vora K, Schindler J et al. Systemic hypothermia to prevent radiocontrast nephropathy (from the COOL-RCN randomized trial). Am. J. Cardiol. 108(5), 741–746 (2011).
  MedlineGoogle Scholar
• 48. Er F, Nia AM, Dopp H et al. Ischemic preconditioning for prevention of contrast medium-induced nephropathy: randomized pilot RenPro Trial (Renal Protection Trial). Circulation 126(3), 296–303 (2012).
  Medline CASGoogle Scholar
• 49. Merten GJ, Burgess WP, Gray LV et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 291(19), 2328–2334 (2004).
  Medline CASGoogle Scholar
• 50. Briguori C, Airoldi F, D'Andrea D et al. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation 115(10), 1211–1217 (2007).
  Medline CASGoogle Scholar
• 51. Spargias K, Alexopoulos E, Kyrzopoulos S et al. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation 110(18), 2837–2842 (2004).
  Medline CASGoogle Scholar
• 52. Neumayer HH, Junge W, Küfner A, Wenning A. Prevention of radiocontrast-media-induced nephrotoxicity by the calcium channel blocker nitrendipine: a prospective randomised clinical trial. Nephrol. Dial. Transplant. 4(12), 1030–1036 (1989).
  Medline CASGoogle Scholar
• 53. Stone GW, McCullough PA, Tumlin JA et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA 290(17), 2284–2291 (2003).
  Medline CASGoogle Scholar
• 54. Briguori C, Colombo A, Airoldi F et al. N-Acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity. J. Am. Coll. Cardiol. 44(4), 762–765 (2004).
  Medline CASGoogle Scholar
• 55. Caixeta A, Dogan O, Weisz G. Contrast-induced nephropathy: protective role of fenoldopam. Clin. Exp. Pharmacol. Physiol. 39(6), 497–505 (2012).
  Medline CASGoogle Scholar
• 56. Kapoor A, Sinha N, Sharma RK et al. Use of dopamine in prevention of contrast induced acute renal failure–a randomised study. Int. J. Cardiol. 53(3), 233–236 (1996).
  Medline CASGoogle Scholar
• 57. Kurnik BR, Allgren RL, Genter FC, Solomon RJ, Bates ER, Weisberg LS. Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy. Am. J. Kidney Dis. 31(4), 674–680 (1998).
  Medline CASGoogle Scholar
• 58. Morikawa S, Sone T, Tsuboi H et al. Renal protective effects and the prevention of contrast-induced nephropathy by atrial natriuretic peptide. J. Am. Coll. Cardiol. 53(12), 1040–1046 (2009).
  Medline CASGoogle Scholar
• 59. Bagshaw SM, Ghali WA. Theophylline for prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Arch. Intern. Med. 165(10), 1087–1093 (2005).
  MedlineGoogle Scholar
• 60. Attallah N, Yassine L, Musial J, Yee J, Fisher K. The potential role of statins in contrast nephropathy. Clin. Nephrol. 62(4), 273–278 (2004).
  Medline CASGoogle Scholar
• 61. Jo S-H, Koo B-K, Park J-S et al. Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial – a randomized controlled study. Am. Heart J. 155(3), 499.e1–8 (2008).
  MedlineGoogle Scholar
• 62. Toso A, Maioli M, Leoncini M et al. Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease. Am. J. Cardiol. 105(3), 288–292 (2010).
  Medline CASGoogle Scholar
• 63. Lindsay J, Apple S, Pinnow EE et al. Percutaneous coronary intervention-associated nephropathy foreshadows increased risk of late adverse events in patients with normal baseline serum creatinine. Catheter. Cardiovasc. Interv. 59(3), 338–343 (2003).
  MedlineGoogle Scholar
• 64. Mehran R, Aymong ED, Nikolsky E et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. Am. Coll. Cardiol. 44(7), 1393–1399 (2004).
  MedlineGoogle Scholar
• 65. Marenzi G, Assanelli E, Campodonico J et al. Contrast volume during primary percutaneous coronary intervention and subsequent contrast-induced nephropathy and mortality. Ann. Int. Med. 150(3), 170–177 (2009). • Important paper to show the importance of contrast dose.
  MedlineGoogle Scholar
• 66. Cigarroa RG, Lange RA, Williams RH, Hillis LD. Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am. J. Med. 86(6 Pt 1), 649–652 (1989).
  Medline CASGoogle Scholar
• 67. Lee S-R, Zhuo H, Zhang Y, Dahl N, Dardik A, Ochoa Chaar CI. Risk factors and safe contrast volume thresholds for postcontrast acute kidney injury after peripheral vascular interventions. J. Vasc. Surg. 72(2), 603–610.e1 (2020).
  MedlineGoogle Scholar
• 68. Kooiman J, Seth M, Share D, Dixon S, Gurm HS. The association between contrast dose and renal complications post PCI across the continuum of procedural estimated risk. PLOS ONE 9(3), e90233 (2014). •• Very important showing contrast dose is important.
  MedlineGoogle Scholar
• 69. Kane GC, Doyle BJ, Lerman A, Barsness GW, Best PJ, Rihal CS. Ultra-low contrast volumes reduce rates of contrast-induced nephropathy in patients with chronic kidney disease undergoing coronary angiography. J. Am. Coll. Cardiol. 51(1), 89–90 (2008). •• Very important reference showing that the amount of contrast is important in the pathogenesis of CIN.
  MedlineGoogle Scholar
• 70. Manske CL, Sprafka JM, Strony JT, Wang Y. Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am. J. Med. 89(5), 615–620 (1990).
  Medline CASGoogle Scholar
• 71. Rozenbaum Z, Benchetrit S, Rozenbaum E, Neumark E, Mosseri M, Pereg D. Ultra-low contrast volume for patients with advanced chronic kidney disease undergoing coronary procedures. Nephron 138(4), 296–302 (2018).
  MedlineGoogle Scholar
• 72. Kelly SC, Li S, Stys TP, Thompson PA, Stys AT. Reduction in contrast nephropathy from coronary angiography and percutaneous coronary intervention with ultra-low contrast delivery using an automated contrast injector system. J. Invasive Cardiol. 28(11), 446–450 (2016).
  MedlineGoogle Scholar
• 73. Azzalini L, Laricchia A, Regazzoli D et al. Ultra-low contrast percutaneous coronary intervention to minimize the risk for contrast-induced acute kidney injury in patients with severe chronic kidney disease. J. Invasive Cardiol. 31(6), 176–182 (2019). •• Very important showing even ultra small amount of contrast can cause contrast-induced nephropathy.
  MedlineGoogle Scholar
• 74. Mariani J, Guedes C, Soares P et al. Intravascular ultrasound guidance to minimize the use of iodine contrast in percutaneous coronary intervention: the MOZART (Minimizing cOntrast utiliZation With IVUS Guidance in coRonary angioplasTy) randomized controlled trial. JACC Cardiovasc. Interv. 7(11), 1287–1293 (2014).
  MedlineGoogle Scholar
• 75. Do C. Intravenous contrast: friend or foe? A review on contrast-induced nephropathy. Adv. Chronic Kidney Dis. 24(3), 147–149 (2017).
  MedlineGoogle Scholar
• 76. Mehran R, Faggioni M, Chandrasekhar J et al. Effect of a contrast modulation system on contrast media use and the rate of acute kidney injury after coronary angiography. JACC Cardiovasc. Interv. 11(16), 1601–1610 (2018).
  MedlineGoogle Scholar
• 77. Gurm HS, Mavromatis K, Bertolet B et al. Minimizing radiographic contrast administration during coronary angiography using a novel contrast reduction system: a multicenter observational study of the DyeVertTM plus contrast reduction system. Catheter. Cardiovasc. Interv. 93(7), 1228–1235 (2019).
  MedlineGoogle Scholar
• 78. Gurm HS, Smith D, Share D et al. Impact of automated contrast injector systems on contrast use and contrast-associated complications in patients undergoing percutaneous coronary interventions. JACC Cardiovasc. Interv. 6(4), 399–405 (2013).
  MedlineGoogle Scholar
• 79. Minsinger KD, Kassis HM, Block CA, Sidhu M, Brown JR. Meta-analysis of the effect of automated contrast injection devices versus manual injection and contrast volume on risk of contrast-induced nephropathy. Am. J. Cardiol. 113(1), 49–53 (2014).
  MedlineGoogle Scholar
• 80. Stub D, Duffy SJ, Kaye DM. Device-based therapy in the prevention of contrast-induced nephropathy. Interv. Cardiol. Clin. 3(3), 421–428 (2014).
  MedlineGoogle Scholar
• 81. Sirajuddin A, Chen MY, White CS, Arai AE. Coronary venous anatomy and anomalies. J. Cardiovasc. Comput. Tomogr. 14(1), 80–86 (2020).
  MedlineGoogle Scholar
• 82. Shah SS, Teague SD, Lu JC, Dorfman AL, Kazerooni EA, Agarwal PP. Imaging of the coronary sinus: normal anatomy and congenital abnormalities. Radiographics 32(4), 991–1008 (2012).
  MedlineGoogle Scholar
• 83. Boonyasirinant T, Halliburton SS, Schoenhagen P, Lieber ML, Flamm SD. Absence of coronary sinus tributaries in ischemic cardiomyopathy: an insight from multidetector computed tomography cardiac venographic study. J. Cardiovasc. Comput. Tomogr. 10(2), 156–161 (2016).
  MedlineGoogle Scholar
• 84. Younger JF, Plein S, Crean A, Ball SG, Greenwood JP. Visualization of coronary venous anatomy by cardiovascular magnetic resonance. J. Cardiovasc. Magn. Reson. 11(1), 26 (2009).
  MedlineGoogle Scholar
• 85. Saremi F, Muresian H, Sánchez-Quintana D. Coronary veins: comprehensive CT-anatomic classification and review of variants and clinical implications. Radiographics 32(1), E1–32 (2012).
  MedlineGoogle Scholar
• 86. Movahed M-R, Wong J, Molloi S. Removal of iodine contrast from coronary sinus in swine during coronary angiography. J. Am. Coll. Cardiol. 47(2), 465–7; 88 (2006). •• Very important reference successfully showing contrast removal from coronary sinus in swine model.
  MedlineGoogle Scholar
• 87. Michishita I, Fujii Z. A novel contrast removal system from the coronary sinus using an adsorbing column during coronary angiography in a porcine model. J. Am. Coll. Cardiol. 47(9), 1866–1870 (2006).
  MedlineGoogle Scholar
• 88. Chang H, Hassan AHM, Kim YL et al. A novel technique for endovascular detection and removal of radiographic contrast during angiography. J. Invasive Cardiol. 21(7), 314–318 (2009).
  MedlineGoogle Scholar
• 89. Meyer M, Dauerman HL, Bell SP, Lewinter MM, Lustgarten DL. Coronary venous capture of contrast during angiography. J. Interv. Cardiol. 19(5), 401–404 (2006).
  MedlineGoogle Scholar
• 90. Danenberg HD, Lotan C, Varshitski B, Rosenheck S, Weiss AT. Removal of contrast medium from the coronary sinus during coronary angiography: feasibility of a simple and available technique for the prevention of nephropathy. Cardiovasc. Revasc. Med. 9(1), 9–13 (2008). •• Very important reference showing successful contrast removal in human.
  MedlineGoogle Scholar
• 91. Duffy SJ, Ruygrok P, Juergens CP et al. Removal of contrast media from the coronary sinus attenuates renal injury after coronary angiography and intervention. J. Am. Coll. Cardiol. 56(6), 525–526 (2010).
  MedlineGoogle Scholar
• 92. Diab OA, Helmy M, Gomaa Y, El-Shalakany R. Efficacy and safety of coronary sinus aspiration during coronary angiography to attenuate the risk of contrast-induced acute kidney injury in predisposed patients. Circ. Cardiovasc. Interv. 10(1), e004348 (2017).
  MedlineGoogle Scholar
• 93. Watson T, Burd JS, Ruygrok PN. Prevention of contrast induced nephropathy during coronary angiography with a coronary sinus contrast removal system sited from the femoral vein. Int. J. Cardiol. 165(1), e9–10 (2013). •• Another very important study in human.
  MedlineGoogle Scholar
• 94. Juergens CP, Winter JP, Nguyen-Do P et al. Nephrotoxic effects of iodixanol and iopromide in patients with abnormal renal function receiving N-acetylcysteine and hydration before coronary angiography and intervention: a randomized trial. Int. Med. J. 39(1), 25–31 (2009).
  Medline CASGoogle Scholar
• 95. Matsuhashi H, Hasebe N, Kawamura Y. The effect of intermittent coronary sinus occlusion on coronary sinus pressure dynamics and coronary arterial flow. Jpn Circ. J. 56(3), 272–285 (1992).
  Medline CASGoogle Scholar
• 96. Pantely GA, Bristow JD, Ladley HD, Anselone CG. Effect of coronary sinus occlusion on coronary flow, resistance, and zero flow pressure during maximum vasodilatation in swine. Cardiovasc. Res. 22(2), 79–86 (1988).
  Medline CASGoogle Scholar
• 97. Langenberg CJM, Pietersen HG, Geskes G, Wagenmakers AJM, Soeters PB, Durieux M. Coronary sinus catheter placement: assessment of placement criteria and cardiac complications. Chest 124(4), 1259–1265 (2003).
  MedlineGoogle Scholar
• 98. Sethna DH, Moffitt EA. An appreciation of the coronary circulation. Anesth. Analg. 65(3), 294–305 (1986).
  Medline CASGoogle Scholar
• 99. Specchia G, De Servi S, Poma E et al. Clinical application of monitoring techniques: coronary sinus blood flow monitoring. Can. J. Cardiol. Jul(Suppl. A), 170A–172A (1986).
  Google Scholar
• 100. Zheng Z, Wu B, Chen Q et al. The feasibility and safety of a simple method for coronary sinus blood sampling during catheter ablation of arrhythmias. Ann. Transl. Med. 10(4), 170 (2022).
  Medline CASGoogle Scholar